Sigut

Protecting Val-Cit from Neutrophil Elastase: One Residue, Two Problems Solved

November 17, 2026

Valine-citrulline is the most widely used cleavable linker in antibody-drug conjugates. It is in brentuximab vedotin, in enfortumab vedotin, and in a large proportion of the clinical pipeline. The design intent is clear: the dipeptide is a substrate for cathepsin B, a protease concentrated inside the lysosome, so the payload should be released after internalisation and not before.

The problem is that cathepsin B is not the only enzyme that recognises it.

The wrong enzyme in the wrong place

Neutrophil elastase is a serine protease released by activated neutrophils and present in circulation. It cleaves the same bond that cathepsin B is meant to cleave, but it does so extracellularly, in the blood, before the ADC has reached its target.

The consequence is premature payload release, and the toxicity that follows is not random. Free payload liberated in the vicinity of neutrophils and neutrophil precursors contributes directly to neutropenia, which is among the most common dose-limiting toxicities reported for Val-Cit-based ADCs. The linker that was designed to confine payload release to the tumour is, in part, releasing it into the compartment least able to tolerate it.

A recent Patent Highlights article by Anna C. Renner and Robert B. Kargbo reviews a patent that addresses this directly, and the chemistry is pleasingly economical.

val-cit-linker-neutrophil-elastase-resistant-acidic-residue-adc

The design: add one residue at the right end

The approach is to extend the standard dipeptide at its N-terminus with one additional residue, specifically an acidic β-homoamino acid or an acidic α-methylamino acid. β-Homoglutamic acid is the worked example.

That residue sits between the PEG or antibody-attachment portion of the linker and the Val-Cit sequence itself, giving an architecture that runs:

PEG – X(acidic residue) – Val-Cit – PABC – payload

The extra residue is reported to block neutrophil elastase from cleaving the linker, while leaving the Val-Cit sequence accessible to the intracellular proteases that are supposed to release the payload at the tumour. The selectivity comes from the difference in how the two enzymes approach the substrate: elastase requires particular access to the residues upstream of the scissile bond, and an acidic, backbone-extended residue in that position interferes with productive binding in a way that lysosomal cathepsin activity tolerates.

In other words, the modification does not make the linker more stable in a general sense. It makes it selectively invisible to one enzyme. That is a more useful outcome than simply slowing all cleavage, which would blunt the release the ADC depends on.

The part we find most elegant

The same residue does a second job.

A β-homoglutamate carries a side-chain carboxylic acid. That acid can be left free, in which case it contributes negative charge and hydrophilicity directly, or it can be used as an attachment point, coupled through an amide bond to a linear or branched PEG chain.

Hydrophobicity is the chronic constraint in linker-payload design. High DAR constructs aggregate, clear quickly and show poor pharmacokinetics, which is why so much effort goes into PEG spacers, sugar units, charged residues and branched architectures. We have looked at several versions of this problem, including the high-DAR exatecan system in AV-DL055 and the branching and polarity work in Merck’s exatecan linker papers.

Here, one residue addresses the off-target cleavage problem and provides the handle for solving the hydrophobicity problem. Each atom added to a linker costs something in synthesis, stability and characterisation, so a modification that earns its place twice is worth noting.

The supporting data

The concept was tested with two mechanistically different payloads, MMAF and exatecan, which suggests the approach is not tied to a single payload class. In HER2-positive xenograft models, constructs built on this platform showed improved tumour growth inhibition compared with comparator ADCs, together with favourable circulation half-life, which is the pharmacokinetic signature one would expect if premature cleavage has genuinely been reduced.

The patent describes the platform as compatible with auristatins, maytansinoids, topoisomerase I inhibitors and further payload classes. That breadth is plausible given that the modification sits on the linker side, upstream of the payload attachment, and does not depend on payload chemistry.

What it says about linker design more generally

The broader lesson is about assumptions. Val-Cit has been used for two decades on the premise that its cleavage is driven by intracellular cathepsin B. That premise is correct but incomplete, and the incomplete part has a clinical cost measured in neutropenia.

The instructive move is not to abandon a chemistry that works, but to identify which enzyme is causing the off-target problem and design specifically against that enzyme while preserving the on-target mechanism. The same logic applies elsewhere. Our article on exo-cleavable linkers describes a different structural answer to the same category of question, and the β-glucuronidase-cleavable linkers we covered previously avoid peptidase recognition altogether by using a different class of trigger.

For any programme running a Val-Cit linker, the practical question is whether elastase-mediated cleavage has actually been measured, in plasma, with the specific construct in hand, rather than assumed to be negligible.

How SigutLabs can help

This is precisely the kind of chemistry we build for clients: cleavable linkers designed around the proteases a given ADC will actually encounter, rather than around the one it is meant to encounter. Modified dipeptide and tripeptide sequences, unnatural and β-homoamino acid residues, PABC self-immolative spacers and PEG or branched hydrophilic units are routine work for our team.

We offer custom ADC linker design and synthesis from route scouting through to purified material, and we supply ADC payloads including monomethyl auristatin E and exatecan mesylate through our e-shop.

If off-target cleavage is costing your programme therapeutic window, let’s connect.

References:

OUR CASE STUDY

Scale-up to accelerate drug discovery

Our experience helped overcome development hurdles for potential cancer & mental health drugs.

Read more

Empowering neuro research with pro-N6pA

Sigut Labs scaled up pro-N6pA production, simplifying AMPylation research & boosting accessibility.

Read more

ADC development leaps with new linkers

Novel linker design expedited ADC advancement, leading to promising lead compounds faster.

Read more

Lincomycin derivative scale-up

Over 30 g of the desired product with exceptional purity was obtained through our optimized procedure.

Read more

Purifying 350 kg of vitamin K2 oil

Our innovative scale-up technology helped to reduce the client’s purification process from days to hours.

Read more

Our services

What we excel in so you don’t have to

Thumbnail image Custom synthesis Thumbnail image Custom synthesis

Custom synthesis

Providing for a custom synthesis of previously reported molecules using described synthetic procedures.

View more
Thumbnail image Contract research Thumbnail image Contract research

Contract research

Developing novel synthetic routes to provide undescribed compounds in organic, bioorganic, and medicinal chemistry.

View more
Thumbnail image Scale-Up Thumbnail image Scale-Up

Scale-Up

Helping you go from lab scales to an industrial scale by applying our cutting-edge instrumentation.

View more
Thumbnail image ADC linkers Thumbnail image ADC linkers

ADC linkers

Power your antibody drug conjugates with bespoke linker chemistry

View more
Thumbnail image Chemical consulting Thumbnail image Chemical consulting

Chemical consulting

De-risk your decisions with lab-backed chemical consulting services

View more
Contact
Kryštof

Get in touch

Krystof Sigut, CEO and Founder
arrow

Our Experts

Profile image Krystof Sigut
Krystof Sigut
- CEO and Founder -
International chemical practitioner eager to restore Czech chemistry's global prestige. Contact Krystof for inquiries, NDA signing, or business matters.
Profile image Petr Slavik
Petr Slavik
- Head of Research -
Synthetic chemistry pro with a decade's diverse lab expertise. For offers, research discussions, or detailed insights, reach out to Petr directly.

Partners & distributors

logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner